162 related articles for article (PubMed ID: 37802566)
1. Safety, tolerability, pharmacokinetics, and immunological activity of dual-combinations and triple-combinations of anti-HIV monoclonal antibodies PGT121, PGDM1400, 10-1074, and VRC07-523LS administered intravenously to HIV-uninfected adults: a phase 1 randomised trial.
Sobieszczyk ME; Mannheimer S; Paez CA; Yu C; Gamble T; Theodore DA; Chege W; Yacovone M; Hanscom B; Heptinstall J; Seaton KE; Zhang L; Miner MD; Eaton A; Weiner JA; Mayer K; Kalams S; Stephenson K; Julg B; Caskey M; Nussenzweig M; Gama L; Barouch DH; Ackerman ME; Tomaras GD; Huang Y; Montefiori D;
Lancet HIV; 2023 Oct; 10(10):e653-e662. PubMed ID: 37802566
[TBL] [Abstract][Full Text] [Related]
2. Safety and antiviral activity of triple combination broadly neutralizing monoclonal antibody therapy against HIV-1: a phase 1 clinical trial.
Julg B; Stephenson KE; Wagh K; Tan SC; Zash R; Walsh S; Ansel J; Kanjilal D; Nkolola J; Walker-Sperling VEK; Ophel J; Yanosick K; Borducchi EN; Maxfield L; Abbink P; Peter L; Yates NL; Wesley MS; Hassell T; Gelderblom HC; deCamp A; Mayer BT; Sato A; Gerber MW; Giorgi EE; Gama L; Koup RA; Mascola JR; Monczor A; Lupo S; Rolle CP; Arduino R; DeJesus E; Tomaras GD; Seaman MS; Korber B; Barouch DH
Nat Med; 2022 Jun; 28(6):1288-1296. PubMed ID: 35551291
[TBL] [Abstract][Full Text] [Related]
3. Safety and pharmacokinetics of broadly neutralising human monoclonal antibody VRC07-523LS in healthy adults: a phase 1 dose-escalation clinical trial.
Gaudinski MR; Houser KV; Doria-Rose NA; Chen GL; Rothwell RSS; Berkowitz N; Costner P; Holman LA; Gordon IJ; Hendel CS; Kaltovich F; Conan-Cibotti M; Gomez Lorenzo M; Carter C; Sitar S; Carlton K; Gall J; Laurencot C; Lin BC; Bailer RT; McDermott AB; Ko SY; Pegu A; Kwon YD; Kwong PD; Namboodiri AM; Pandey JP; Schwartz R; Arnold F; Hu Z; Zhang L; Huang Y; Koup RA; Capparelli EV; Graham BS; Mascola JR; Ledgerwood JE;
Lancet HIV; 2019 Oct; 6(10):e667-e679. PubMed ID: 31473167
[TBL] [Abstract][Full Text] [Related]
4. A Randomised Clinical Trial of the Safety and Pharmacokinetics of VRC07-523LS Administered via Different Routes and Doses (HVTN 127/HPTN 087).
Walsh SR; Gay CL; Karuna ST; Hyrien O; Skalland T; Mayer KH; Sobieszczyk ME; Baden LR; Goepfert PA; Del Rio C; Pantaleo G; Andrew P; Karg C; He Z; Lu H; Paez CA; Baumblatt JAG; Polakowski LL; Chege W; Janto S; Han X; Huang Y; Dumond J; Ackerman ME; McDermott AB; Flach B; Piwowar-Manning E; Seaton K; Tomaras GD; Montefiori DC; Gama L; Mascola JR;
medRxiv; 2024 Jan; ():. PubMed ID: 38260276
[TBL] [Abstract][Full Text] [Related]
5. Assessing the safety and pharmacokinetics of the anti-HIV monoclonal antibody CAP256V2LS alone and in combination with VRC07-523LS and PGT121 in South African women: study protocol for the first-in-human CAPRISA 012B phase I clinical trial.
Mahomed S; Garrett N; Karim QA; Zuma NY; Capparelli E; Baxter C; Gengiah T; Archary D; Samsunder N; Doria-Rose N; Moore P; Williamson C; Barouch DH; Fast PE; Pozzetto B; Hankins C; Carlton K; Ledgerwood J; Morris L; Mascola J; Abdool Karim S
BMJ Open; 2020 Nov; 10(11):e042247. PubMed ID: 33243815
[TBL] [Abstract][Full Text] [Related]
6. Safety and pharmacokinetics of VRC07-523LS administered via different routes and doses (HVTN 127/HPTN 087): A Phase I randomized clinical trial.
Walsh SR; Gay CL; Karuna ST; Hyrien O; Skalland T; Mayer KH; Sobieszczyk ME; Baden LR; Goepfert PA; Del Rio C; Pantaleo G; Andrew P; Karg C; He Z; Lu H; Paez CA; Baumblatt JAG; Polakowski LL; Chege W; Anderson MA; Janto S; Han X; Huang Y; Dumond J; Ackerman ME; McDermott AB; Flach B; Piwowar-Manning E; Seaton K; Tomaras GD; Montefiori DC; Gama L; Mascola JR;
PLoS Med; 2024 Jun; 21(6):e1004329. PubMed ID: 38913710
[TBL] [Abstract][Full Text] [Related]
7. Neutralization profiles of HIV-1 viruses from the VRC01 Antibody Mediated Prevention (AMP) trials.
Mkhize NN; Yssel AEJ; Kaldine H; van Dorsten RT; Woodward Davis AS; Beaume N; Matten D; Lambson B; Modise T; Kgagudi P; York T; Westfall DH; Giorgi EE; Korber B; Anthony C; Mapengo RE; Bekker V; Domin E; Eaton A; Deng W; DeCamp A; Huang Y; Gilbert PB; Gwashu-Nyangiwe A; Thebus R; Ndabambi N; Mielke D; Mgodi N; Karuna S; Edupuganti S; Seaman MS; Corey L; Cohen MS; Hural J; McElrath MJ; Mullins JI; Montefiori D; Moore PL; Williamson C; Morris L
PLoS Pathog; 2023 Jun; 19(6):e1011469. PubMed ID: 37384759
[TBL] [Abstract][Full Text] [Related]
8. Safety and Pharmacokinetics of Monoclonal Antibodies VRC07-523LS and PGT121 Administered Subcutaneously for Human Immunodeficiency Virus Prevention.
Mahomed S; Garrett N; Capparelli EV; Osman F; Harkoo I; Yende-Zuma N; Gengiah TN; Archary D; Samsunder N; Baxter C; Mkhize NN; Modise T; Carlton K; McDermott A; Moore PL; Karim QA; Barouch DH; Fast PE; Mascola JR; Ledgerwood JE; Morris L; Abdool Karim SS
J Infect Dis; 2022 Aug; 226(3):510-520. PubMed ID: 35134995
[TBL] [Abstract][Full Text] [Related]
9. Validation of a Triplex Pharmacokinetic Assay for Simultaneous Quantitation of HIV-1 Broadly Neutralizing Antibodies PGT121, PGDM1400, and VRC07-523-LS.
Wesley MS; Chiong KT; Seaton KE; Arocena CA; Sawant S; Hare J; Hernandez K; Rojas M; Heptinstall J; Beaumont D; Crisafi K; Nkolola J; Barouch DH; Sarzotti-Kelsoe M; Tomaras GD; Yates NL
Front Immunol; 2021; 12():709994. PubMed ID: 34504492
[TBL] [Abstract][Full Text] [Related]
10. Assessing the safety and pharmacokinetics of the monoclonal antibodies, VRC07-523LS and PGT121 in HIV negative women in South Africa: study protocol for the CAPRISA 012A randomised controlled phase I trial.
Mahomed S; Garrett N; Capparelli E; Baxter C; Zuma NY; Gengiah T; Archary D; Moore P; Samsunder N; Barouch DH; Mascola J; Ledgerwood J; Morris L; Abdool Karim S
BMJ Open; 2019 Jul; 9(7):e030283. PubMed ID: 31272988
[TBL] [Abstract][Full Text] [Related]
11. Safety and pharmacokinetics of escalating doses of neutralising monoclonal antibody CAP256V2LS administered with and without VRC07-523LS in HIV-negative women in South Africa (CAPRISA 012B): a phase 1, dose-escalation, randomised controlled trial.
Mahomed S; Garrett N; Capparelli EV; Osman F; Mkhize NN; Harkoo I; Gengiah TN; Mansoor LE; Baxter C; Archary D; Yende-Zuma N; Samsunder N; Carlton K; Narpala S; McDermott AB; Doria-Rose NA; Moore PL; Morris L; Abdool Karim Q; Mascola JR; Abdool Karim SS
Lancet HIV; 2023 Apr; 10(4):e230-e243. PubMed ID: 37001964
[TBL] [Abstract][Full Text] [Related]
12. Phase 1 trial evaluating safety and pharmacokinetics of HIV-1 broadly neutralizing mAbs 10E8VLS and VRC07-523LS.
Awan SF; Pegu A; Strom L; Carter CA; Hendel CS; Holman LA; Costner PJ; Trofymenko O; Dyer R; Gordon IJ; Rothwell RSS; Hickman SP; Conan-Cibotti M; Doria-Rose NA; Lin BC; O'Connell S; Narpala SR; Almasri CG; Liu C; Ko S; Kwon YD; Namboodiri AM; Pandey JP; Arnold FJ; Carlton K; Gall JG; Kwong PD; Capparelli EV; Bailer RT; McDermott AB; Chen GL; Koup RA; Mascola JR; Coates EE; Ledgerwood JE; Gaudinski MR;
JCI Insight; 2024 Apr; 9(7):. PubMed ID: 38587079
[TBL] [Abstract][Full Text] [Related]
13. Extended safety and tolerability of subcutaneous CAP256V2LS and VRC07-523LS in HIV-negative women: study protocol for the randomised, placebo-controlled double-blinded, phase 2 CAPRISA 012C trial.
Mahomed S; Garrett N; Potloane D; Sikazwe IT; Capparelli E; Harkoo I; Gengiah TN; Zuma NY; Osman F; Mansoor L; Archary D; Myeni N; Radebe P; Samsunder N; Doria-Rose N; Carlton K; Gama L; Koup RA; Narpala S; Serebryannyy L; Moore P; Williamson C; Pozzetto B; Hankins C; Morris L; Karim QA; Abdool Karim S
BMJ Open; 2023 Aug; 13(8):e076843. PubMed ID: 37640457
[TBL] [Abstract][Full Text] [Related]
14. Safety, pharmacokinetics, and immunological activities of multiple intravenous or subcutaneous doses of an anti-HIV monoclonal antibody, VRC01, administered to HIV-uninfected adults: Results of a phase 1 randomized trial.
Mayer KH; Seaton KE; Huang Y; Grunenberg N; Isaacs A; Allen M; Ledgerwood JE; Frank I; Sobieszczyk ME; Baden LR; Rodriguez B; Van Tieu H; Tomaras GD; Deal A; Goodman D; Bailer RT; Ferrari G; Jensen R; Hural J; Graham BS; Mascola JR; Corey L; Montefiori DC; ;
PLoS Med; 2017 Nov; 14(11):e1002435. PubMed ID: 29136037
[TBL] [Abstract][Full Text] [Related]
15. Subtle Longitudinal Alterations in Env Sequence Potentiate Differences in Sensitivity to Broadly Neutralizing Antibodies following Acute HIV-1 Subtype C Infection.
Mandizvo T; Gumede N; Ndlovu B; Ndlovu S; Mann JK; Chopera DR; Singh L; Dong KL; Walker BD; Ndhlovu ZM; Lavine CL; Seaman MS; Gounder K; Ndung'u T
J Virol; 2022 Dec; 96(24):e0127022. PubMed ID: 36453881
[TBL] [Abstract][Full Text] [Related]
16. Neutralization diversity of HIV-1 Indian subtype C envelopes obtained from cross sectional and followed up individuals against broadly neutralizing monoclonal antibodies having distinct gp120 specificities.
Mullick R; Sutar J; Hingankar N; Deshpande S; Thakar M; Sahay S; Ringe RP; Mukhopadhyay S; Patil A; Bichare S; Murugavel KG; Srikrishnan AK; Goyal R; Sok D; Bhattacharya J
Retrovirology; 2021 May; 18(1):12. PubMed ID: 33990195
[TBL] [Abstract][Full Text] [Related]
17. Safety and tolerability of AAV8 delivery of a broadly neutralizing antibody in adults living with HIV: a phase 1, dose-escalation trial.
Casazza JP; Cale EM; Narpala S; Yamshchikov GV; Coates EE; Hendel CS; Novik L; Holman LA; Widge AT; Apte P; Gordon I; Gaudinski MR; Conan-Cibotti M; Lin BC; Nason MC; Trofymenko O; Telscher S; Plummer SH; Wycuff D; Adams WC; Pandey JP; McDermott A; Roederer M; Sukienik AN; O'Dell S; Gall JG; Flach B; Terry TL; Choe M; Shi W; Chen X; Kaltovich F; Saunders KO; Stein JA; Doria-Rose NA; Schwartz RM; Balazs AB; Baltimore D; Nabel GJ; Koup RA; Graham BS; Ledgerwood JE; Mascola JR;
Nat Med; 2022 May; 28(5):1022-1030. PubMed ID: 35411076
[TBL] [Abstract][Full Text] [Related]
18. Sensitivity to Broadly Neutralizing Antibodies of Recently Transmitted HIV-1 Clade CRF02_AG Viruses with a Focus on Evolution over Time.
Stefic K; Bouvin-Pley M; Essat A; Visdeloup C; Moreau A; Goujard C; Chaix ML; Braibant M; Meyer L; Barin F
J Virol; 2019 Jan; 93(2):. PubMed ID: 30404804
[TBL] [Abstract][Full Text] [Related]
19. Ex vivo sensitivity to broadly neutralizing antibodies and anti-CD4 antibody UB-421 of infectious viral isolates from people living with multidrug-resistant HIV.
Rai MA; Blazkova J; Justement JS; Shi V; Kennedy BD; Manning MR; McLaughlin M; Sneller MC; Pau AK; Moir S; Chun TW
EBioMedicine; 2024 Jun; 104():105151. PubMed ID: 38728839
[TBL] [Abstract][Full Text] [Related]
20. Systematic Assessment of Antiviral Potency, Breadth, and Synergy of Triple Broadly Neutralizing Antibody Combinations against Simian-Human Immunodeficiency Viruses.
Berendam SJ; Styles TM; Morgan-Asiedu PK; Tenney D; Kumar A; Obregon-Perko V; Bar KJ; Saunders KO; Santra S; De Paris K; Tomaras GD; Chahroudi A; Permar SR; Amara RR; Fouda GG
J Virol; 2021 Jan; 95(3):. PubMed ID: 33177194
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
